Open AccessBK polyomavirus‐neutralizing activity of intravenous immunoglobulin products derived from donated blood in Japan
Author(s) -
Urayama T.,
Takahashi K.,
Ideno S.,
Yunoki M.,
Saito M.,
Numakura K.,
Inoue T.,
Satoh S.,
Sakai K.
Publication year - 2016
Publication title -
isbt science series
Language(s) - English
Resource type - Journals
eISSN - 1751-2824
pISSN - 1751-2816
DOI - 10.1111/voxs.12294
Subject(s) - titer , antibody , polyomavirus infections , virology , bk virus , neutralizing antibody , medicine , population , immunology , kidney , kidney transplantation , environmental health
Background and Objectives BK polyomavirus ( BKV ) causes BKV ‐associated nephropathy and haemorrhagic cystitis, subsequent to BKV reactivation. Intravenous immunoglobulin products ( IVI g), manufactured from the plasma of over ten thousand donors, may contain antibodies against BKV . However, the antibody titres and batch‐to‐batch variations in IVI g across the manufacturing year are unknown. This study aims to determine the BKV ‐neutralizing activity of IVI g from donated blood in Japan and its trend over the past several years. Materials and Methods A reliable measurement method was established to quantitatively determine neutralizing activity using the human lung (carcinoma) cell line, A549 and the Gardner strain of BKV . Six lots of IVI g and four lots of pooled plasma were used as the source material for this study. Results The mean neutralizing titre against BKV in pooled plasma was 3·4 ± 0·1 log 10 and that in IVI g was 4·1 ± 0·1 log 10 . The titres of IVI g lots manufactured from 1999 to 2010 were stable. Conclusion IVI g derived from donated blood in Japan demonstrated high neutralizing activity against BKV , and its titre was maintained over the duration of 10 years, suggesting high prevalence of BKV among the donor population in Japan. Further studies are required to clarify the clinical implications of this neutralizing activity in IVI g.